July 3, 2013 – An interventional x-ray system with live-image guidance and featuring low-dose settings received 510(k) clearance from the United States (U.S.) Food and Drug Administration (FDA).
Royal Philips announced that will now market its AlluraClarity live image guidance system in the U.S. Philips’ AlluraClarity system with its ClarityIQ technology is designed to provide high-quality imaging for a comprehensive range of clinical procedures, achieving high visibility at low x-ray dose levels for patients of all sizes. To reflect the cost pressures that modern hospitals and health systems face, ClarityIQ technology will also be available as an upgrade for the majority of Philips’ installed base of monoplane and biplane interventional x-ray systems.
“All patients treated via x-ray guided interventions benefit from the advantage of low radiation exposure, but it is especially important when you are treating patients who have to undergo lengthy and complex procedures,” said Dr. Marco van Strijen, interventional radiologist at the St. Antonius Hospital Utrecht/Nieuwegein, the Netherlands. “We have been using Philips’ AlluraClarity system for more than a year now and have really grown to appreciate the low dose settings. This technology is making a difference where it really matters."
AlluraClarity’s low x-ray dose settings are designed to help clinicians better manage their patients’ and their own exposure to x-ray radiation. This achievement is the result of a multi-year development program that formed part of Philips’ continuous investment in healthcare R&D, totaling EUR 803 million in 2012.
Back To Top